Novartis AG (NOVN) Fair Value: Near Fair Value at CHF 113.4

Novartis AG Fair Value Analysis: Near Fair Value at Current Levels

Novartis AG (NOVN), the Swiss pharmaceutical leader, currently trades at CHF 119.04 against our calculated fair value of CHF 113.4. This places the stock just 4.7% above fair value, earning a verdict of "near fair value" alongside a robust Quality Score of 81/100. Investors seeking a stable healthcare holding with innovation-driven growth may find the current pricing reasonable.

What Novartis Does and Its Core Business

Novartis focuses on five therapeutic areas: oncology, cardiology-renal, immunology, neuroscience and hematology. Its portfolio blends established blockbusters with fast-growing launches in radioligand therapy, targeted protein degradation and cell/gene therapies. Recent highlights include the completed acquisition of Avidity Biosciences, expanding capabilities in muscle diseases.

Recent Performance and Market Context

In Q1 2026, Novartis reported net sales of USD 13.1 billion, down 1% in USD terms (5% at constant currency) as strong volume growth from priority brands was offset by US generic erosion on Entresto, Promacta and Tasigna. Core operating income declined but full-year 2026 guidance was reaffirmed: low single-digit sales growth and low single-digit decline in core operating income. Positive June 2026 pipeline updates, including successful trials for Rhapsido and Del-brax, have supported sentiment.

Key Valuation Drivers Behind Our Fair Value

Our multi-model approach incorporates discounted cash flow, comparable multiples and dividend discount models. Primary drivers include:

• Resilient free cash flow generation exceeding USD 3 billion in Q1 alone.
• Double-digit growth in high-margin launches (Kisqali +55% cc, Pluvicto +70% cc).
• Pharma-sector multiples tempered by generic headwinds and acquisition-related debt.
• Strong capital allocation and 34%+ return on equity metrics.

These factors anchor the CHF 113.4 fair value estimate, balancing near-term earnings pressure against long-term innovation potential.

Main Risks to Consider

Patent cliffs and generic competition remain the biggest near-term challenge, particularly the multi-billion-dollar Entresto erosion. Integration risks from the USD 12 billion Avidity deal could pressure margins. Currency fluctuations (CHF strength) and regulatory hurdles in key markets also warrant monitoring. Analyst consensus leans Hold with price targets clustered around USD 141–153, reflecting cautious optimism.

Balanced Verdict on Novartis AG

Novartis AG offers a high-quality business trading close to our fair value. The 81/100 Quality Score reflects durable competitive advantages and solid execution, yet the modest premium suggests limited immediate upside. Long-term holders may appreciate the diversified pipeline and reaffirmed guidance, while value-focused investors could await pullbacks. For the latest personalized valuation, check the free Fair Value Calculator to run scenarios on Novartis AG or explore our full suite of 21 models.

Discover more stocks and refine your analysis with our fair value calculator.

Frequently Asked Questions

Is Novartis AG undervalued or overvalued right now?

According to our fair value model, Novartis AG (NOVN) trades slightly above fair value at CHF 119.04 versus CHF 113.4, indicating it is near fair value with limited upside of -4.7%.

What are the main risks for Novartis stock in 2026?

Key risks include ongoing US generic erosion on legacy products like Entresto, integration of the large Avidity acquisition, patent cliffs, and potential margin pressure despite reaffirmed guidance.

How does Novartis' pipeline support long-term growth?

Priority brands such as Kisqali, Pluvicto, Kesimpta, Scemblix and Leqvio delivered strong double-digit growth in Q1 2026, helping offset generic headwinds while new pipeline readouts in oncology and rare diseases bolster future prospects.